Sultan Alouffi

Prof. Sultan Alouffi

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
Saheem AhmadSaheem Ahmad
Saheem Ahmad
Mohd Yasir KhanMohd Yasir Khan
Mohd Yasir Khan
ZRZeeshan Rafi
Zeeshan Rafi
HKHamda Khan
Hamda Khan
ZSZeba Siddiqui
Zeba Siddiqui
MKMohd Shahnawaz Khanf
Mohd Shahnawaz Khanf

Verified
Journal Article
Open access
PDF file
Arbab HusainArbab Husain
Arbab Husain
SASultan Alouffi
Sultan Alouffi
AKAfreen Khanam
Afreen Khanam
RMRihab Mohamed
Rihab Mohamed
GTGyanendra Tripathi
Gyanendra Tripathi
Saheem AhmadSaheem Ahmad
Saheem Ahmad
Diabetes is a long-term metabolic disorder characterized by persistently elevated blood sugar levels. Chronic hyperglycemia enhances glucose–protein interactions, leading to the formation of advanced glycation end products (AGEs), which form irreversible cross-links with a wide variety of macromolecules, and accumulate rapidly in the body tissues. Thus, the objective of this study was to assess the therapeutic properties of C-phycocyanin (C-PC) obtained from Plectonema species against oxidative stress, glycation, and type 2 diabetes mellitus (T2DM) in a streptozotocin (STZ)-induced diabetic Wistar rat. Forty-five days of C-PC administration decreased levels of triglycerides (TGs), blood glucose, glycosylated hemoglobin, (HbA1c), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), liver and kidney function indices, and raised body weight in diabetic rats. C-PC suppressed biochemical glycation markers, as well as serum carboxymethyllysine (CML) and fluorescent AGEs. Additionally, C-PC maintained the redox state by lowering lipid peroxidation and protein-bound carbonyl content (CC), enhancing the activity of high-density lipoprotein cholesterol (HDL-C) and renal antioxidant enzymes, and preserving retinal and renal histopathological characteristics. Thus, we infer that C-PC possesses antidiabetic and antiglycation effects in diabetic rats. C-PC may also act as an antidiabetic and antiglycation agent in vivo that may reduce the risk of secondary diabetic complications.

1 June 2017 in Current Vascular Pharmacology
Verified
Journal Article
Closed access
Saheem AhmadSaheem Ahmad
Saheem Ahmad
ZSZeba Siddiqui
Zeba Siddiqui
SRShahnawaz Rehman
Shahnawaz Rehman
Mohd Yasir KhanMohd Yasir Khan
Mohd Yasir Khan
HKHamda Khan
Hamda Khan
Mohd SaeedMohd Saeed
Mohd Saeed
In diabetic patients, accelerated glycation process causes increased oxidative stress and chronic hyperglycaemia that play a vital role in the diabetic complications. Extensive intracellular and extracellular generation of these glycated products finally form advanced glycation end products (AGEs). The accumulation of AGEs is related with the intensive risk for microvascular and macrovascular injuries for diabetic patients. Therefore, formation of AGEs results from the condensation of reducing sugars with biomolecules like nucleic acids, proteins, and lipids which potentially alter their function. Effect of AGEs formation is also related with the cross-linking that promotes vascular stiffness which modifies the vascular structure and long-life function of proteins. Formation of AGEs may also activate specific receptors, like receptor for AGEs (RAGEs) that induce the intracellular signaling which enhance the oxidative stress and also the amplification of key pro-sclerotic and pro-inflammatory cytokines. From last few decades, a huge number of pre-clinical studies related with the AGEs formation in the diabetic patients have been performed. The target for such trials was the formation and degradation of AGEs, and its interaction with RAGEs. This review focuses on the mechanism how these AGEs exert detrimental nuisance in the diabetes, as well as deal with existing strategies to disrupt the action or formation of AGEs. Therefore, the unseen role of both the early and advanced stage glycation in the diabetic Vasculopathy is described. We have also illustrated how the glycation inhibition results in the delay of the development of vascular complications in diabetic patients.

1 August 2018 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
Mohd Yasir KhanMohd Yasir Khan
Mohd Yasir Khan
SASultan Alouffi
Sultan Alouffi
Saheem AhmadSaheem Ahmad
Saheem Ahmad

25 April 2018 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
SKSaif Khan
Saif Khan
TBTulika Bhardwaj
Tulika Bhardwaj
PSPallavi Somvanshi
Pallavi Somvanshi
RMRaju K. Mandal
Raju K. Mandal
SDSajad Ahmad Dar
Sajad Ahmad Dar
Shafiul HaqueShafiul Haque
Shafiul Haque

19 January 2022 in BioMed Research International
Verified
Journal Article
Open access
PDF file
Saheem AhmadSaheem Ahmad
Saheem Ahmad
SASultan Alouffi
Sultan Alouffi
SKSaif Khan
Saif Khan
MKMahvish Khan
Mahvish Khan
RARihab Akasha
Rihab Akasha
Mohd Yasir KhanMohd Yasir Khan
Mohd Yasir Khan
Hundreds of millions of people around the globe are afflicted by diabetes mellitus. The alteration in glucose fixation process might result into hyperglycaemia and could affect the circulating plasma proteins to undergo nonenzymatic glycation reaction. If it is unchecked, it may lead to diabetes with increase in advanced glycation end products (AGEs). Therefore, the present study was designed to inhibit the diabetes and glycation by using natural antioxidant “ellagic acid” (EA). In this study, we explored the antidiabetes and antiglycation potential of EA in both in vitro (EA at micromolar concentration) and in vivo systems. The EA concentrations of 10 and 20 mg kg-1B.W./day were administered orally for 25 days to alloxan‐induced diabetic rats, a week after confirmation of stable diabetes in animals. Intriguingly, EA supplementation in diabetic rats reversed the increase in fasting blood sugar (FBS) and hemoglobin A1c (HbA1c) level. EA also showed an inhibitory role against glycation intermediates including dicarbonyls, as well as AGEs, investigated in a glycation mixture with in vitro and in vivo animal plasma samples. Additionally, EA treatment resulted in inhibition of lipid peroxidation‐mediated malondialdehyde (MDA) and conjugated dienes (CD). Furthermore, EA exhibited an antioxidant property, increased the level of plasma glutathione (GSH), and also helped to decrease histological changes evaluated by histoimmunostaining of animal kidney tissues. The results from our investigation clearly indicates the antiglycative property of EA, suggesting EA as an adequate inhibitor of glycation and diabetes, which can be investigated further in preclinical settings for the treatment and management of diabetes‐associated complications.